Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922678 | 0.86 | ATM (0.43) | NPC1MAPTLMNAALDH1A1HTT | |
| SCHEMBL16920142 | 0.80 | DGAT1 (0.46) | NPC1MAPTLMNADGAT1ALDH1A1 | |
| SCHEMBL16922682 | 0.78 | PPARG (0.38) | NPC1MAPTGAAPKMKDM4E | |
| SCHEMBL30363805 | 0.73 | PPARG (0.40) | NPC1MAPTGAAKDM4ELMNA | |
| SCHEMBL16920118 | 0.72 | NPC1 (0.39) | NPC1MAPTLMNADGAT1ALDH1A1 | |
| SCHEMBL14709937 | 0.72 | NPC1 (0.48) | NPC1MAPTGAAKDM4ELMNA | |
| SCHEMBL30363639 | 0.72 | AAK1 (0.42) | MAPTGAAKDM4ELMNADGAT1 | |
| SCHEMBL17963471 | 0.70 | DGAT1 (0.44) | NPC1MAPTGAAPKMKDM4E | |
| SCHEMBL16661173 | 0.69 | DGAT1 (0.69) | NPC1DGAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16792683 | 0.69 | NOD2 (0.42) | NPC1MAPTKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141906-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO. , LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
| US-9890119-B2 | Indole and azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20150203450-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203450-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAA1, PRKAA2, PRKAB1 | NPC1 2996/4885MAPT 4209/4885GAA 4207/4885 |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | NPC1 1209/4885MAPT 3941/4885GAA 1135/4885 |
| US-20180141906-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAA1, PRKAA2, PRKAG3 | NPC1 3834/4885MAPT 4480/4885GAA 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.